长春高新：GenSci134注射液境内生产药品注册临床试验申请获批

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its self-developed drug, GenSci134 injection, aimed at treating growth hormone deficiency (GHD) [1] Company Summary - Jinsai Pharmaceutical's GenSci134 injection is classified as a Class 1 biological product and is intended for the treatment of GHD, including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions such as idiopathic short stature (ISS) [1]